| Nov 6 |
Perrigo's Q3 Earnings Fall Short of Estimates, Sales View Updated
|
| Nov 6 |
BIIB vs. MYGN: Which Stock Is the Better Value Option?
|
| Nov 5 |
Are Investors Undervaluing Biogen (BIIB) Right Now?
|
| Nov 4 |
Biogen (BIIB) Loses -6.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
|
| Nov 2 |
Executive reshuffles: BIIB, USB and WES
|
| Nov 1 |
Biogen partner Eisai completes FDA submissions for injectable Alzheimer’s therapy
|
| Nov 1 |
Biogen Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
| Oct 31 |
Biogen Q3 Earnings Review: Why I Remain Optimistic Despite Difficult Quarter
|
| Oct 31 |
Biogen down as Morgan Stanley cuts rating on sluggish Alzheimer’s drug launch
|
| Oct 31 |
Biogen slips as Morgan Stanley downgrades on Leqembi launch
|
